{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-006773","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2026-06-23T21:00:27+00:00","discovered_at":"2026-06-23T21:02:00.293657+00:00","generated_at":"2026-06-23T21:02:31.527323+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NeOnc receives UAE IND approval for NEO100; Phase 2a data expected by end of July 2026","bullets":["UAE DOH granted IND status for NEO100 across adult Phase 1-2 and pediatric studies for recurrent gliomas.","NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations.","Top-line Phase 2a data from fully enrolled NEO100-01 trial expected by end of July 2026.","Authorization follows recent UAE IND clearance for NEO212, expanding development footprint."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-006773","json":"https://secwatch.observer/filing/0001829126-26-006773.json","markdown":"https://secwatch.observer/filing/0001829126-26-006773.md","text":"https://secwatch.observer/filing/0001829126-26-006773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626006773/0001829126-26-006773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626006773/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:02:31.527323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}